Chillon J M, Baumbach G L
Department of Pathology, University of Iowa College of Medicine and Cardiovascular Center, Iowa City, Iowa 52242, USA.
Hypertension. 1999 Mar;33(3):856-61. doi: 10.1161/01.hyp.33.3.856.
We examined the effects of an angiotensin-converting enzyme inhibitor, perindopril, and a beta-blocker, propranolol, on cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP). The structure and mechanics of cerebral arterioles were examined in untreated Wistar-Kyoto rats (WKY) and SHRSP that were untreated or treated for 3 months with a high (2 mg/kg per day) or a low (0.3 mg/kg per day) dose of perindopril or propranolol (250 mg/kg per day) alone or in combination with the low dose of perindopril. We measured pressure, external diameter, and cross-sectional area of the vessel wall (CSA) in maximally dilated (with EDTA) cerebral arterioles. Treatment of SHRSP with the high dose of perindopril or the combination of propranolol and the low dose of perindopril normalized cerebral arteriolar mean pressure (50+/-1 [mean+/-SEM] and 43+/-2 mm Hg vs 50+/-1 mm Hg in WKY and 94+/-3 mm Hg in untreated SHRSP; P<0.05), pulse pressure (15+/-1 and 16+/-1 mm Hg vs 13+/-1 mm Hg in WKY and 35+/-1 mm Hg in untreated SHRSP; P<0.05), and CSA (1103+/-53 and 1099+/-51 microm2, respectively, vs 1057+/-49 microm2 in WKY and 1281+/-62 microm2 in untreated SHRSP; P<0.05). In contrast, treatment of SHRSP with the low dose of perindopril or propranolol alone did not normalize arteriolar pulse pressure (24+/-1 and 21+/-1 mm Hg) and failed to prevent increases in CSA (1282+/-77 and 1267+/-94 microm2). Treatment with either dose of perindopril or the combination of propranolol and perindopril significantly increased external diameter in cerebral arterioles of SHRSP (99+/-3, 103+/-2, and 98+/-3 microm vs 87+/-2 microm in untreated SHRSP; P<0.05), whereas propranolol alone did not (94+/-3 microm; P>0.05). These findings suggest that effects of angiotensin-converting enzyme inhibitors on cerebral arteriolar hypertrophy in SHRSP may depend primarily on their effects on arterial pressure, particularly pulse pressure, whereas their effects on cerebral arteriolar remodeling (defined as a reduction in external diameter) may be pressure independent.
我们研究了血管紧张素转换酶抑制剂培哚普利和β受体阻滞剂普萘洛尔对易卒中型自发性高血压大鼠(SHRSP)脑小动脉的影响。在未治疗的Wistar-Kyoto大鼠(WKY)和未治疗或用高剂量(2mg/kg/天)或低剂量(0.3mg/kg/天)的培哚普利或普萘洛尔(250mg/kg/天)单独或与低剂量培哚普利联合治疗3个月的SHRSP中,研究了脑小动脉的结构和力学特性。我们测量了最大扩张(用乙二胺四乙酸)的脑小动脉的压力、外径和血管壁横截面积(CSA)。用高剂量培哚普利或普萘洛尔与低剂量培哚普利联合治疗SHRSP可使脑小动脉平均压力正常化(WKY为50±1[平均值±标准误]和43±2mmHg,未治疗的SHRSP为50±1mmHg,未治疗的SHRSP为94±3mmHg;P<0.05),脉压(WKY为15±1和16±1mmHg,未治疗的SHRSP为13±1mmHg,未治疗的SHRSP为35±1mmHg;P<0.05)和CSA(分别为1103±53和1099±51μm²,WKY为1057±49μm²,未治疗的SHRSP为1281±62μm²;P<0.05)。相比之下,用低剂量培哚普利或单独用普萘洛尔治疗SHRSP不能使小动脉脉压正常化(24±1和21±1mmHg),也不能阻止CSA增加(1282±77和1267±94μm²)。用任何一种剂量的培哚普利或普萘洛尔与培哚普利联合治疗均显著增加了SHRSP脑小动脉的外径(99±3、103±2和98±3μm,未治疗的SHRSP为87±2μm;P<0.05),而单独用普萘洛尔则没有(94±3μm;P>0.05)。这些发现表明,血管紧张素转换酶抑制剂对SHRSP脑小动脉肥大的影响可能主要取决于它们对动脉血压,特别是脉压的影响,而它们对脑小动脉重塑(定义为外径减小)的影响可能与压力无关。